Written by Helen Cooke, Helen Seers and the CAM-Cancer Consortium.
Updated December 13, 2011

Laetrile

What is Laetrile?

Scientific/ common names

Laetrile is also known as: Apricot pits, Vitamin B17, mandelonitrile-beta-glucuronide (semi-synthetic), mendelonitrile beta-D-gentiobioside (natural product), laevorotatory and mandelonitrile, purasin, Amygdalina, and nitriloside.

Ingredients

Laetrile is an acronym used to describe a purified, semi-synthetic form of Amygdalin (LAEvorotatory and mandeloniTRILE). Amygdalin is a naturally occurring plant compound that contains sugar and produces cyanide and is found primarily in the kernels of apricots, peaches and bitter almonds and also in plants such as lima beans, clover and sorghum.

Laetrile in the US is not the same thing as Laetrile/Amygdalin used in Mexico. This is because the “Laetrile” used in Mexico may actually be simply crushed apricot kernels, rather than the semi-synthetic form of Laetrile (mandelonitrile-beta-glucuronide) used in the US. Therefore, not all studies of laetrile may have tested the same substance, making conclusions difficult. Incorrect labels have been found and samples tested have been contaminated with bacteria, toxins and other substances1. Several foods may also contain Laetrile in low and safe amounts as part of a balanced diet.

Application and dosage

Laetrile is usually administered either orally as a pill, or by injecting into a vein or muscle. Treatment is usually started intravenously for a period of time (approximately two to three weeks) and then provided orally (maximum of 5 kernels at one time, or 1 gram of Laetrile) as a maintenance therapy. Laetrile can also be used in enema form, or can be applied directly to skin lesions.

History

Amygdalin was first identified and isolated by French chemists in 1830 and was used as an anti-cancer agent in 1845 in Russia. By the 1920s Amygdalin had reached the US, but the early pill form was considered to be too toxic and its use was discontinued. In the 1950s an apparently non-toxic, semi-synthetic intravenous form of Amygdalin was developed by Dr Krebs in the US, and this became known as Laetrile. In the 1970s Laetrile gained popularity either as a single-agent treatment or as part of a metabolic therapy programme (that also included high-dose vitamin supplements and enzymes)2.

Claims of efficacy/mechanism(s) of action/alleged indication

Powerful claims of anti-cancer effects have been made by distributors and hospitals in Mexico where Laetrile is used. Proponents suggest that cyanide is responsible for the anti-cancer action, which is released from the enzymatic degradation of laetrile3. However, none of these claims have been supported by research evidence. Supporters of Laetrile often use anthropological evidence to back up their anti-cancer claims. Such evidence comes from studies of remote cultures who consume high levels of foods rich in nitrisolides (Amygdalin), for instance, the Hunza, aboriginal Eskimo, the Hopi and Navajo Indians4. However, it is important to remember that, even though studies of these populations have reported low incidences of cancer, this must be viewed in context and other unmeasured variables taken into account.

Cyanide released from enzymatic degradation of laetrile or amygdalin is believed to be the ingredient responsible for the alleged anti-cancer action. Proponents claim that malignant cells are specifically vulnerable to cyanogenic glycosides because of two characteristics: a higher level of beta-glucosidases and beta-glucuronidase compared to normal cells, which would lead to a more rapid intracellular release of cyanide from laetrile or amygdalin and a deficiency in rhodanese, an enzyme that converts cyanide into the harmless compound thiocyanate. Another theory claims that cancer develops due to the deficiency of a vitamin, named "vitamin B17", which was the name that the chemist E.T. Krebs gave to laetrile5.

Prevalence of use

The popularity of Laetrile reached its peak in 1978 when it was reported that 70,000 people had been treated with it2. Current prevalence data are not available.

Legal issues

Laetrile has had a very long and detailed history. This includes inaccurate theories of how it works, conspiracy theories of unpublished research supporting its use, banning of its use in the US by the Food and Drug Administration (FDA), and the jailing of many supporters and suppliers (including Dr Krebs himself). The controversy continues with vendors’ internet sites being shut down and injunctions being served. In the UK, according to the Medicines and Healthcare products Regulatory Agency (MHRA), the status of Amygdalin/Laetrile/B17 is that it is a prescription only medicine. It is not a banned substance but it is unlicensed, and as such its availability is restricted through a prescription from a doctor. This means that a doctor can supply it to a patient should he or she considers it an appropriate treatment, however, the doctor does this under their own responsibility. No licensed products contain the Laetrile/Amygdalin/B17 substance.

Cost and expenditures

Laetrile tablets are available via the internet for approximately 100 USD for 100 tablets. Since there are no clear guidelines on dosage and length of treatment, it is not possible to give an overall cost for laetrile treatment.

Citation

Helen Cooke, Helen Seers, CAM-Cancer Consortium. Laetrile [online document]. http://www.cam-cancer.org/CAM-Summaries/Dietary-approaches/Laetrile. December 13, 2011.

Document history

References

  1. Davignon, JP, Trissel, LA, & Kleinman, LM. Pharmaceutical assessment of amygdalin (Laetrile) products. Cancer Treatment Reports. 1978; 62 (1): 99-104.
  2. Chandler, RF, Phillipson, JD & Anderson, LA. Controversial Laetrile. Journal of Pharmacology. 1984; 232: 330-332
  3. Ellison, NM, Byar, DP, & Newell, GR. Special report on Laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective Laetrile analysis.New England Journal of Medicine. 1978; 7;299 (10):549-52.
  4. McCarrison, SR. “Nutrition and National Health.” Journal of the Royal Society of Arts. 1936. lxxxiv, 1047, 1067, 1087.
  5. Milazzo S, Ernst E, Lejeune S, Boehm K, Horneber M. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD005476. DOI: 10.1002/14651858.CD005476.pub3
  6. Milazzo S, Lejeune S, Ernst E. Laetrile for cancer: a systematic review of the clinical evidence. Support Care Cancer. 2007 Jun;15(6):583-95.
  7. Moertel, CG, Ames, MM, Kovach, JS, et al. A pharmacologic and toxicological study of amygdalin. Journal of the American Medical Association. 1981. 245 (6): 591-4.
  8. Moertel, CG, Fleming, TR, Rubin, J, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. New England Journal of Medicine. 1982; 306 (4): 201-6.
  9. Kochi, M, Takeuchi, S, Mizutani, T, et al. Antitumor activity of benzaldehyde. Cancer Treatment Reports. 1980; 64 (1): 21-3.
  10. Kochi, M, Isono, N, Niwayama, M, et al. Antitumor activity of a benzaldehyde derivative. Cancer Treatment Reports. 1985; 69 (5): 533-7.
  11. Wodinsky, I, & Swiniarski, JK. Antitumour activity of amygdalin MF (NSC-15780) as a single agent and with beta-glucosidase (NSC-128056) on a spectrum of transplantable rodent tumours. Cancer Chemotherapy Reports. 1975; 59, (5): 939-50.
  12. Overjera, AA., Houchens, DP., Barker, AD. et al. Inactivity of DL- amygdalin against human breast and colon tumor xenografts in athymic (nude mice). Cancer Treatment Reports. 1978; 62 (4): 576-78.
  13. Manner HW, DiSanti SJ, Maggio MI, et al. Amygdalin, vitamin A and enzyme induced regression of murine mammary adenocarcinomas. Journal of Manipulative Physiolgical Therapy. 1978; 1 (4): 246-8.
  14. Bhatti RA, Ablin RJ, & Guinan PD. Tumour-associated directed immunity in prostatic cancer: effect of amygdalin. IRCS Medical Science research Biochemistry. 1981; 9 (1): 19.
  15. Biaglow JE, & Durand RE. The enhanced radiation response of an in vitro tumour model by cyanide released from hydrolysed amygdalin. International Journal of Radiation Biology. 1978; 33 (4): 397-401.
  16. Syrigos KN, Rowlinson-Busza G, & Epenetos AA. In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. International Journal of Cancer. 1998; 78 (6): 712-9.
  17. Braico, KT, Humbert, JR, Terplan, KL, & Lehotay, JM. Laetrile intoxication: report of a fatal case, New England Journal of Medicine. 1979; 1; 300 (5): 238-40.
  18. Sadoff, L, Fuchs, K, & Hollander, J, Rapid death associated with Laetrile ingestion, Journal of the American Medical Association. 1978; 14; 239 (15): 1532.
  19. Lee, M, Berger, HW, Givre, HL, et al. Near fatal Laetrile intoxication: Complete recovery with supportive treatment, Mount Sinai Journal of Medicine. 1982; 49 (4): 305-307.
  20. Bromley J, Hughes BG, Leong DC, Buckley NA. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother. 2005 Sep;39(9):1566-9.
  21. Newmark J, Brady, RO, Grimley, PM, Gal, AE, Waller, SG, & Thistlethwaite, JR. Amygdalin (Laetrile) and pruasin beta-glucosidases: Distribution in germ free rat and in human tumor tissue. Proceedings of the National Academy of Sciences of the United States of America. 1981; 78 (10): 6513-6.